Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SOLESENCE, INC.NANX · Entity 7041 | Director · President, CEO | December 31, 2024 | January 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SOLESENCE, INC.
Report date December 31, 2024 · Filed January 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 · Expires 2031-12-31 | Direct | 22,500 |
Reported balance
After 2024-12-31 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-12-31 · Grant · Acquired 22,500 · Balance 22,500 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2026-02-23 | Direct | 69,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 69,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2027-02-21 | Direct | 81,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 81,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2028-05-23 | Direct | 90,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 90,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.51 · Expires 2029-05-22 | Direct | 16,500 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 16,500 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.45 · Expires 2027-06-18 | Direct | 90,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 90,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.17 · Expires 2028-12-28 | Direct | 90,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 90,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.17 · Expires 2029-12-20 | Direct | 72,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 72,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.61 · Expires 2030-12-27 | Direct | 12,600 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 12,600 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common StockSEC Table I · non-derivative | IndirectSpouse's IRA | 1,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,000 |
| Common StockSEC Table I · non-derivative | Direct | 207,450 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 207,450 |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 06, 2022 Filed Dec 9, 2022 01:10 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 4,816 | $0.42 Strike: $0.42 | $1,998.64 |
DisclosureSEC source: 0001209191-22-060425 · doc4.xml · derivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,310 Underlying: Common Stock · 26,126 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| December 06, 2022 Filed Dec 9, 2022 01:10 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 4,816 | $1.21 | $5,827.36 |
DisclosureSEC source: 0001209191-22-060425 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 F2 · date: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. F3 · price: These shares were sold in four separate transactions, all at $1.21 per share. Read SEC document |
| December 06, 2022 Filed Dec 9, 2022 01:10 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 4,816 | $0.42 | $1,998.64 |
DisclosureSEC source: 0001209191-22-060425 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F1 · price: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:46 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 1,000 | $0.42 Strike: $0.42 | $415.00 |
DisclosureSEC source: 0001209191-22-059718 · doc4.xml · derivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,126 Underlying: Common Stock · 27,126 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:46 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 1,000 | $1.50 | $1,500.00 |
DisclosureSEC source: 0001209191-22-059718 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 F2 · date: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. F3 · price: The price reported is a weighted average price. These shares were sold through multiple transactions, two in all, at prices ranging from $1.50 to $1.51. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:46 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 1,000 | $0.42 | $415.00 |
DisclosureSEC source: 0001209191-22-059718 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F1 · price: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 02:35 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 3,000 | $0.42 Strike: $0.42 | $1,245.00 |
DisclosureSEC source: 0001209191-22-058923 · doc4.xml · derivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,126 Underlying: Common Stock · 30,126 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 02:35 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 3,000 | $1.39 | $4,170.00 |
DisclosureSEC source: 0001209191-22-058923 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 F2 · date: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. F4 · price: The price reported is a weighted average price. These shares were sold through multiple transactions, four in all, at prices ranging from $1.35 to $1.41. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 02:35 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 3,000 | $0.42 | $1,245.00 |
DisclosureSEC source: 0001209191-22-058923 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 23, 2022 Filed Nov 29, 2022 02:35 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 1,500 | $0.42 Strike: $0.42 | $622.50 |
DisclosureSEC source: 0001209191-22-058923 · doc4.xml · derivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,126 Underlying: Common Stock · 31,626 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 23, 2022 Filed Nov 29, 2022 02:35 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 1,500 | $1.40 | $2,100.00 |
DisclosureSEC source: 0001209191-22-058923 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 F2 · date: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. F3 · price: The price reported is a weighted average price. These shares were sold through multiple transactions, five in all, at prices ranging from $1.40 to $1.40. Read SEC document |
| November 23, 2022 Filed Nov 29, 2022 02:35 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 1,500 | $0.42 | $622.50 |
DisclosureSEC source: 0001209191-22-058923 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F1 · price: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 2,600 | $0.42 Strike: $0.42 | $1,079.00 |
DisclosureSEC source: 0001209191-22-058550 · doc4.xml · derivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,626 Underlying: Common Stock · 34,226 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 2,600 | $1.38 | $3,588.00 |
DisclosureSEC source: 0001209191-22-058550 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 F2 · date: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. F4 · price: The price reported is a weighted average price. These shares were sold through multiple transactions, five in all, at prices ranging from $1.36 to $1.40. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 2,600 | $0.42 | $1,079.00 |
DisclosureSEC source: 0001209191-22-058550 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 18, 2022 Filed Nov 23, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 10,000 | $0.42 Strike: $0.42 | $4,150.00 |
DisclosureSEC source: 0001209191-22-058550 · doc4.xml · derivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,226 Underlying: Common Stock · 44,226 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 18, 2022 Filed Nov 23, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 10,000 | $1.40 | $14,000.00 |
DisclosureSEC source: 0001209191-22-058550 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 F2 · date: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. F3 · price: The price reported is a weighted average price. These shares were sold through multiple transactions, eleven in all, at prices ranging from $1.37 to $1.45. Read SEC document |
| November 18, 2022 Filed Nov 23, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 10,000 | $0.42 | $4,150.00 |
DisclosureSEC source: 0001209191-22-058550 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F1 · price: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 9,400 | $0.42 Strike: $0.42 | $3,901.00 |
DisclosureSEC source: 0001209191-22-057747 · doc4.xml · derivative · entry 19 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,226 Underlying: Common Stock · 53,626 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 500 | $1.30 | $650.00 |
DisclosureSEC source: 0001209191-22-057747 · doc4.xml · nonDerivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 500 | $0.42 | $207.50 |
DisclosureSEC source: 0001209191-22-057747 · doc4.xml · nonDerivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 5 | $0.42 Strike: $0.42 | $2.08 |
DisclosureSEC source: 0001209191-22-057747 · doc4.xml · derivative · entry 18 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,626 Underlying: Common Stock · 53,631 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 5 | $1.62 | $8.10 |
DisclosureSEC source: 0001209191-22-057747 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 5 | $0.42 | $2.08 |
DisclosureSEC source: 0001209191-22-057747 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 15, 2022 Filed Nov 18, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 2,300 | $0.42 Strike: $0.42 | $954.50 |
DisclosureSEC source: 0001209191-22-057747 · doc4.xml · derivative · entry 17 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,631 Underlying: Common Stock · 55,931 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 15, 2022 Filed Nov 18, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 2,300 | $1.80 | $4,140.00 |
DisclosureSEC source: 0001209191-22-057747 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 15, 2022 Filed Nov 18, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 2,300 | $0.42 | $954.50 |
DisclosureSEC source: 0001209191-22-057747 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F1 · price: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 6,500 | $0.42 Strike: $0.42 | $2,697.50 |
DisclosureSEC source: 0001209191-22-056830 · doc4.xml · derivative · entry 15 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,931 Underlying: Common Stock · 62,431 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 6,500 | $1.90 | $12,350.00 |
DisclosureSEC source: 0001209191-22-056830 · doc4.xml · nonDerivative · entry 12 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 6,500 | $0.42 | $2,697.50 |
DisclosureSEC source: 0001209191-22-056830 · doc4.xml · nonDerivative · entry 11 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 6,586 | $0.42 Strike: $0.42 | $2,733.19 |
DisclosureSEC source: 0001209191-22-056830 · doc4.xml · derivative · entry 14 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,431 Underlying: Common Stock · 69,017 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 4,986 | $1.95 | $9,722.70 |
DisclosureSEC source: 0001209191-22-056830 · doc4.xml · nonDerivative · entry 10 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 1,400 | $1.96 | $2,744.00 |
DisclosureSEC source: 0001209191-22-056830 · doc4.xml · nonDerivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 1,400 | $0.42 | $581.00 |
DisclosureSEC source: 0001209191-22-056830 · doc4.xml · nonDerivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 200 | $1.97 | $394.00 |
DisclosureSEC source: 0001209191-22-056830 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 200 | $0.42 | $83.00 |
DisclosureSEC source: 0001209191-22-056830 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 200 | $0.42 Strike: $0.42 | $83.00 |
DisclosureSEC source: 0001209191-22-056830 · doc4.xml · derivative · entry 13 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,017 Underlying: Common Stock · 69,217 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 200 | $2.10 | $420.00 |
DisclosureSEC source: 0001209191-22-056830 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 200 | $0.42 | $83.00 |
DisclosureSEC source: 0001209191-22-056830 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F1 · price: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 00:20 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 300 | $0.42 Strike: $0.42 | $124.50 |
DisclosureSEC source: 0001209191-22-056269 · doc4.xml · derivative · entry 11 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,217 Underlying: Common Stock · 69,517 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 00:20 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 300 | $2.16 | $648.00 |
DisclosureSEC source: 0001209191-22-056269 · doc4.xml · nonDerivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 00:20 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 300 | $0.42 | $124.50 |
DisclosureSEC source: 0001209191-22-056269 · doc4.xml · nonDerivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 00:20 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 3,000 | $0.42 Strike: $0.42 | $1,245.00 |
DisclosureSEC source: 0001209191-22-056269 · doc4.xml · derivative · entry 10 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,517 Underlying: Common Stock · 72,517 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 00:20 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 3,000 | $2.27 | $6,810.00 |
DisclosureSEC source: 0001209191-22-056269 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 00:20 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 3,000 | $0.42 | $1,245.00 |
DisclosureSEC source: 0001209191-22-056269 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 07, 2022 Filed Nov 10, 2022 00:20 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 1,500 | $0.42 Strike: $0.42 | $622.50 |
DisclosureSEC source: 0001209191-22-056269 · doc4.xml · derivative · entry 9 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,517 Underlying: Common Stock · 74,017 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 07, 2022 Filed Nov 10, 2022 00:20 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 1,500 | $2.03 | $3,045.00 |
DisclosureSEC source: 0001209191-22-056269 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 07, 2022 Filed Nov 10, 2022 00:20 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 1,500 | $0.42 | $622.50 |
DisclosureSEC source: 0001209191-22-056269 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F1 · price: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 04, 2022 Filed Nov 5, 2022 01:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 1,000 | $0.42 Strike: $0.42 | $415.00 |
DisclosureSEC source: 0001209191-22-055875 · doc4.xml · derivative · entry 11 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,017 Underlying: Common Stock · 75,017 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 04, 2022 Filed Nov 5, 2022 01:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 1,000 | $2.28 | $2,280.00 |
DisclosureSEC source: 0001209191-22-055875 · doc4.xml · nonDerivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.